FDA Clears Abionic’s IVD CAPSULE PSP for the early detection of Sepsis Epalinges, Switzerland, October 01, 2024 – Abionic, an emerging medical diagnostics company focused on rapid early detection technologies, announced today that its IVD CAPSULE PSP test has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to accelerate the
A Look at Abionic’s abioSCOPE, a COVID-19 Severity Test Triage Tool Abionic’s abioSCOPE rapid diagnostic test generates results from a single drop of blood in less than five minutes. Image from Abionic. Swiss medtech company Abionic has developed a disease severity and triage tool for the identification of individuals with, or who are at
Swiss Firm Introduces Test to Spot Covid Patients Most at Risk A Swiss firm has introduced a blood test that can help hospitals more quickly pinpoint patients at risk of a severe form of Covid-19 as doctors seek ways to triage and prioritize medical treatment. Abionic SA said Thursday its method can be performed without medical training
ABIONIC'S SEPSIS DIAGNOSTIC TEST COULD BE USEFUL IN COVID-19 Septic shock is one of the major complications of Covid-19. Vaud-based start-up Abionic, specialized in the miniaturization of diagnostic tests, has developed a test that can detect sepsis in five minutes. Abionic's solution detects sepsis in five minutes, which could be useful for severe cases
Abionic integrates first patients in US clinical trial for sepsis diagnosis method Biopôle, Lausanne, Switzerland, 9th January 2020 – Abionic SA, Swiss Medtech firm based in Lausanne, is initiating a pivotal clinical trial in the US for an innovative point-of-care diagnostic method for sepsis to validate the results of a first trial that took place in
Abionic - Five Minutes To Save Lives
Abionic teams up with Genentech to develop rapid Asthma test Abionic has signed an agreement with Genentech to develop and provide rapid Point-of-Care tests for Asthma in the US. The pre-market process for the specific asthma panel will be managed by Abionic while Genentech will fund clinical and regulatory costs. In the U.S., 25 million
Discover Abionic, its team, its technology and its product: the sepsis 5-minute diagnostic platform
Abionic SA: Revolutionizing the World of In Vitro Diagnostics In 2009, more than 100 million Europeans suffered from allergies. Ironically, the sharp rise in allergy-related conditions of recent decades can be traced back to improved hygiene. European public health systems have identified this surge as one of the main factors that put pressure on their infrastructure. In the biomedical
Sepsis kills more people than breast cancer, prostate cancer and AIDS combined. It can affect anyone. To stop sepsis, everyone needs to know about it. Make sure you and your loved ones are aware.